The British Naturopathic Association's annual Study Day on June 23rd 2012 will have the theme of Naturopathic Approaches to Endocrinology. MIfHI graduates, Drs. Tom and Jacqueline Greenfield, are presenting a lecture entitled: A Nutrigenomic Approach to Endocrinology. A summary of their lecture follows:

Medical endocrinologists typically deal with major hormonal imbalances pharmacologically. A reductionistic approach to the body perceives the organ which is producing increased or decreased levels of hormones as the source of the organic dysfunction; the "cure" is either hormone replacement therapy, suppression of excess hormone production or blocking receptor sites. In the same way, nutritional supplementation can be used to make up for deficiencies or excess to directly enhance or suppress the function of specific hormonal pathways. However this is not necessarily treating the patient as a whole: it could be seen as linear thinking, not looking for the reason behind the disturbance in homoeostasis, or whether the cause of the imbalance is still there. As naturopaths how can we support health in the patient with endocrine-related disorders using natural methods and a more holistic approach?

Nutrigenomics has brought a growing awareness of the potential for modification of food intake to promote health and reduce the risk of diet-related diseases. It is a way of altering the expression of genes through nutrition: a nutrigenomic perspective views nutrients as cell-signalling mechanisms which are detected by sensors in the cell: a variation in nutrient levels triggers a cellular mechanism which changes gene expression, protein and metabolite production. This can restore balance in many body systems where the individual's genes have been programmed during gestation to survive in an environment in which they no longer find themselves.

In our presentation we discuss ways of influencing hormonal pathways through diet and nutritional supplementation at the level of the gene using the example of types of thyroid dysfunction and diabetes. We also look at a commonly-supplemented hormone in detail: vitamin D, it's role in many disease processes; we review a hypothesis for the role of vitamin D3 and it's metabolite in dysregulation of androgen and glucocorticoid receptors in autoimmune disease.

Knowing what diseases to prevent and how to address existing illness is the key to individualised medicine. As naturopaths we can target prevention to the specific disease tendencies of the individual rather than assume everyone will get the same illnesses. We present a system devised by Dr. Peter D'Adamo ND which looks at three overriding responses to the environment: reactive, thrifty and tolerant, further refined by gene clusters, or haplotypes, in proximity to the blood group gene on 9q34. We discuss simple in-clinic biomarkers that can be used to assess the patient's epigenetics: how to determine their disease susceptibilities and which preventive measures may be the most appropriate for them; in the presence of an existing disorder, how to know which pathways to upregulate or downregulate through dietary intervention. We also discuss an educational opportunity for practitioners and the informed public to become certified in human individuality.

Other speakers at the event are Dr. Marilyn Glenville Ph.D., nutritionist specialising in women’s health, Alison Cullen, education manager at Bioforce UK, and Marian Baartz MSc., Iridologist. The event is open to non-members of the British Naturopathic Association.

Here's a preview of a guest editorial I was asked to write for the British Naturopathic Journal about where Naturopathy is heading over the next decade:

With the dramatic rise in access to information over the last decade our patients are becoming experts in their own conditions and ways to heal themselves. The increase in patient knowledge means the days where a patient will accept uncritically the word of the physician are coming to an end, particularly where the advice given does not correspond with what they have read or expect to hear.

How does this change our role - how can we keep up with the new expectation of our patients: That we have a knowledge of their disease as detailed as they do and the skills to offer specific treatment? Traditional naturopaths might say stick to the basics: Fresh air; clean water; hydrotherapy; pure diet; exercise; right thinking; fasting when appropriate. This approach will always give the healing power of nature a chance to restore and maintain health in most situations with which we are presented. In reality many people nowadays have the pressure of work, family or other financial and time constraints, and the option to resort to orthodox treatment: They demand something more, a quicker, easier solution to their problems, or advice that they can't get for themselves. Unless we specialise in the naturopathic approach to treating patients with one particular type of condition, how can the polymath respond to this challenge while staying true to the core principles of naturopathy?

The essence of naturopathic philosophy maintains that every patient is unique, and every treatment must be tailored to that individual. As experts in assessing types of patients and with the ability to compare the person in our office with those we have treated before, we are in a good position to judge their differences and similarities to others and recognise the therapeutic significance. Naturopaths have access to tests, experience in taking body measurements, and the ability to interpret the results and offer advice. With genetic testing, orthodox medicine is moving towards a scientific understanding of the patient's individuality, and naturopathic medicine must follow this example. Genetic tests are available for use with functional medicine, but are still relatively expensive and the results often too complex for the average patient to easily relate. Another way to determine patient individuality is to use traditional observations and simple tests that can be done in the clinic - the body has many external signs that can indicate specific tendencies, patterns and needs: Iridology is one system, reflexology another. Despite their regular and efficient use by many practitioners these systems often lack clinical validation as primary assessment tools, a factor which is is frequently being questioned.

One system using scientific measurements of individuality that can be carried out in the clinic while remaining true to core naturopathic concepts is 'The GenoType Diet', a therapeutic system devised by naturopathic physician Dr. Peter D'Adamo. Having evolved from 'The Blood Group Diet', naturopaths using this system will initially classify the patient into one of six major categories based on their blood group; further refinements are then made according to genetic and epigenetic factors determined by simple biometric measurements taken in the consulting room, along with the clinical judgements of the practitioner. An example of this would be D2:D4 ratio: The difference between the second and fourth digit on each hand. Many published papers show how this characteristic can be influenced by hormone levels in-utero; the epigenetic effects last throughout life; measurement simply requires a ruler, and that the patient still has these four fingers. The practitioner can also assess the likelihood of these prenatal influences being due to maternal hormone exposure or hormone-mimicking xenobiotics.

D'Adamo offers this system to practitioners who know and understand his work. Any level of personalisation can be added to the secure online data collection tool according to the patient's requirements or clinical need; a complete dietary and lifestyle report is accessed via a complex database that makes millions of calculations based on how a particular food influences this patient. In addition to calorific value, factors such as enhancement of methylation, histone activation, acetylation requirements or contribution to glycation of a particular dietary component may be factored in according to the genetic tendencies of the patient. If any factors change, for example: The patient's weight; exercise regime; family history; conventional medication prescription; adjustment to the patient's data may result in changes to their recommendations, so the advice can be updated with each clinic visit.

Systems such as this are the future of naturopathic medicine: Patients feel satisfied that they are getting personalised healthcare they can't get elsewhere, while the practitioner can integrate their own favourite therapeutic approach according to individual need. By 2020 this approach may well be standard procedure in naturopathic healthcare.

Dear Dr. Greenfield,

I am a 42 year old woman with RLS. I have it since I was 20, with alternating good and bad periods.

It affects me especially in my sleep. I am a 0+, Gatherer.

Are there any natural supplements I can take which could make a difference?

Thanks and kind regards,

Petra

Restless legs syndrome (RLS) and periodic limb movement disorder are characterized during waking by an irresistible urge to move the legs while awake, and involuntary leg movements while asleep.

For people with a family history of RLS, it is worth considering whether there is a genetic influence on the condition: researchers have found several genetic loci associated with RLS in an autosomal dominant inheritance pattern [1].

One of the genetic influences may involve an increased need for folate [2]. Individuals with polymorphisms for folate metabolism often do better taking an active form of folic acid such as folinate, rather than the commonly available folic acid supplements. Although folic acid improves methylation in all GenoTypes, GT4 Explorers are more prone to folic acid deficiency anaemia; GT1 Hunters and GT6 Nomads may also need folate to slow down their rapidly aging genes [3].

Researchers have also found that iron supplementation may improve the symptoms of RLS [2], reducing fluctuations in dopamine levels in the brain at night. Patients with RLS have lower levels of dopamine and respond to iron administration [4]. Caffeine, nicotine, alcohol and medication that affects dopamine levels may induce RLS as a side effect. It is recommended to check ferritin (iron storage) levels before supplementing with iron, as ferritin levels are often lower than average in RLS sufferers. There are strong indications that a gene regulating dopamine beta hydroxylase activity is linked to the ABO blood group locus [5], and altered dopamine levels may be associated with blood type.

Finally, osteopathic manipulative therapy has been found to decrease spinal facilitation in a small pilot study, relieving symptoms in many patients with RLS [6].

References:
1. Dhawan V, Ali M, Chaudhuri KR. "Genetic aspects of restless legs syndrome." Postgrad Med J. 2006 Oct;82(972):626-9. PubMed
2. Lee KA, Zaffke ME, Baratte-Beebe K.J. "Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron." Womens Health Gend Based Med. 2001 May;10(4):335-41. PubMed
3. Dadamp, P. The GenoType Diet. Broadway Books, 2007, ISBN 978-0-7679-2524-2
4. Patrick LR. "Restless legs syndrome: pathophysiology and the role of iron and folate." Altern Med Rev. 2007 Jun;12(2):101-12. PubMed
5. Wilson AF, Elston RC, Siervogel RM, Tran LD. "Linkage of a gene regulating dopamine-beta-hydroxylase activity and the ABO blood group locus". Am J Hum Genet 1988;42:160-166. PubMed
6. Peters T W, "Restless Legs", Osteopathy Today, October 2001. P12-13.

An extract of the seaweed Lithothamnion corallioides from Ireland has been the subject of a clinical trial with patients suffering from osteoarthritis of the knee.[1] The seaweed extract containing minerals was compared to glucosamine sulfate, and both products demonstrated improvements in those taking them.

Comparing 6-Minute Walking Distances and the WOMAC Knee and Hip Osteoarthritis Index, 70 subjects with moderate to severe osteoarthritis of the knee were placed into 4 random groups and took either the seaweed mineral extract (2400 mg), glucosamine sulfate (1500 mg), both, or a placebo. The seaweed mineral and glucosamine groups demonstrated significant improvements in 6 minute walking distances, but the placebo and combination groups did not.

The WOMAC index grades pain, stiffness and physical function over specific activities. Significant differences were found between groups for pain scores after 12 weeks of treatment. The seaweed extract treatment group showed significantly improved WOMAC pain, stiffness, activity and composite scores over the course of the 12-week treatment. No significant improvements were found for subjects in the placebo group or for subjects in the combination treatment group.

The authors hypothesize that there could be an interaction in the stomach between the alkaline seaweed minerals and the acid glucosamine, which has to ionize in the stomach to be effective.

NAP Phytocal and Clearcal contain minerals from Lithothamnion corallioides, and are suitable for specific or all blood groups.

References:
1. Frestedt JL, Walsh M, Kuskowski MA, Zenk JL. "A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial." Nutr J. 2008 Feb 17;7:9. PMID 18279523

The UK Food Standards Agency (FSA) has issued a press release advising pregnant mothers to limit their intake of coffee and caffeine-containing substances.[1] "Pregnant women are advised to limit their daily caffeine intake to 200mg a day – roughly two mugs of coffee a day" due to a potential link with Foetal Growth Retardation (FGR). This is a reduction from the previous advice of 300 mg per day, following an updated report from the FSA's independent Committee on Toxicity (COT).[2] According to the committee, if there is a causal link then there may be no lower 'safe' limit, but a caffeine intake of less than 200 mg per day during pregnancy may reduce the risk of FGR to less than 2%. FGR is defined as failure of the baby to attain its growth potential as determined by genetic and environmental factors.

The FSA funded research published by the British Medical Journal[3] which measured caffeine intake from all sources (coffee, tea, colas and medication) in pregnant women, and then measured their babies when they were born. The xenobiotic caffeine can be detoxified from the body in four main ways, 3-demethylation being quantitatively the most important: caffeine is converted to paraxanthine by the enzyme cytochrome P450 1A2 (CYP1A2). This is one of the enzymes which often has low activity in the GT4 Explorer GenoType, and is responsible for Explorers being up all night after drinking coffee. The researchers measured the CYP1A2 enzyme activity as the main form of caffeine clearance in the mothers taking part in the study. They found that the mothers with the highest CYP1A2 activity passed the most caffeine and caffeine metabolites to their foetus via the placenta. CYP1A2 activity is absent in the placenta and the fetus.[4] This means that like the GT4 Explorer, the unborn baby won't get much sleep after their mother has drunk coffee.

What is the problem with having smaller babies? It is a well known epigenetic risk factor, as the COT study says:

FGR is an important outcome because it is associated with an increased risk of perinatal mortality and morbidity, including perinatal asphyxia. Moreover, there is epidemiological evidence that FGR correlates with adverse effects in adult life. For example, affected individuals have an increased incidence of metabolic syndrome, manifesting as obesity, hypertension, hypercholesterolemia, cardiovascular disease, and type 2 diabetes.

Smoking and alcohol intake also have a significant effect on the risk of FGR.

References:

1. Food Standards Agency. "Food Standards Agency publishes new caffeine advice for pregnant women." Press release, Monday 3 November 2008.
2. Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. "Statement on the reproductive effects of caffeine". COT statement 2008/04
3. CARE Study Group. "Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study" BMJ 2008;337:a2332
4. Aldridge A, Aranda JV, Neims AH. "Caffeine metabolism in the newborn." Clin Pharmacol Ther. 1979 Apr;25(4):447-53. PMID: 428190